Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624675 | 1.00 | HDAC6 (0.56) | HDAC6HDAC11HDAC7HDAC8HDAC4 | |
| SCHEMBL20096685 | 0.89 | HDAC6 (0.64) | HDAC6HDAC11HDAC7HDAC8HDAC4 | |
| SCHEMBL29624692 | 0.89 | HDAC6 (0.64) | HDAC6HDAC11HDAC7HDAC8HDAC4 | |
| SCHEMBL20096880 | 0.88 | LMNA (0.49) | HDAC6HDAC11HDAC7HDAC8LMNA | |
| SCHEMBL20096429 | 0.78 | HDAC11 (0.56) | HDAC6HDAC11HDAC7HDAC4HDAC9 | |
| SCHEMBL29624652 | 0.78 | HDAC11 (0.70) | HDAC6HDAC11HDAC7HDAC8HDAC4 | |
| SCHEMBL20096684 | 0.78 | HDAC11 (0.53) | HDAC6HDAC11HDAC7HDAC4HDAC9 | |
| SCHEMBL29624706 | 0.78 | HDAC11 (0.56) | HDAC6HDAC11HDAC7HDAC4HDAC9 | |
| SCHEMBL29624722 | 0.78 | HDAC11 (0.65) | HDAC6HDAC11HDAC7HDAC8HDAC4 | |
| SCHEMBL20096425 | 0.78 | HDAC11 (0.65) | HDAC6HDAC11HDAC7HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | HDAC6 6/4885HDAC11 1/4885HDAC7 11/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC6 6/4885HDAC11 1/4885HDAC7 11/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC6 6/4885HDAC11 1/4885HDAC7 11/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC6 6/4885HDAC11 1/4885HDAC7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.